Latest Kaiser Health News Stories
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Sarah Kliff of Vox and Alice Ollstein of Talking Points Memo discuss a proposed administration regulation that seeks to separate Planned Parenthood from federal family planning funds, the final congressional passage of legislation aimed at helping those with terminal illnesses obtain experimental medications, and new government reports on the uninsured and federal health spending. Also, Rovner interviews KHN’s Liz Szabo about the May “Bill of the Month.”
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
Starting in less than two years, if state hospitals haven’t met targets for safety and quality, they’ll risk being excluded from the “in-network” designation of health plans sold on the state’s insurance exchange.
KHN’s Sarah Jane Tribble explains the key elements of the Trump blueprint on CBS News’ “Red & Blue.”
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
Anthem, one of the country’s largest insurers, has cut the reimbursement rate it pays for breast pumps by nearly half, fueling concerns that new moms — especially ones with lower incomes — will not be able to afford the pumps they need.
The Pennsylvania-based health chain Geisinger plans to offer DNA sequencing as part of regular patient care.
Guess who’s back grabbing headlines? Pharmacy benefit managers — those companies that serve as middlemen in the prescription drug pipeline.
The Trump administration is pulling out an old regulation that it believes will be able to meet a key conservative goal: withholding some federal funding for Planned Parenthood in the government’s family planning program.
A crowdsourced investigation by KHN and NPR gives voice to those who are puzzled and outraged by medical invoices.
The first-in-the-nation measure would empower Vermont to set up a wholesale program to import prescription drugs from Canada. But it still will have to get federal buy-in before it is operational.
In a case with possible national repercussions, the state’s attorney general has sued over alleged price gouging, and other legal and legislative challenges are afoot. Sutter is pushing back hard, denying anticompetitive behavior.
A woman with foot pain was floored by the high cost of titanium screws used in her surgery. “Unless the metal [was] mined on an asteroid, I do not know why it should cost that amount,” she says.
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Margot Sanger-Katz of The New York Times and Anna Edney of Bloomberg News discuss the latest on the politics of rising premiums, GOP efforts to take back money from the Children’s Health Insurance Program, and the controversy over new rules requiring calorie information on menus. Plus for extra credit, the panelists recommend their favorite health stories of the week.
The complexity of health insurance coverage rules, along with market trends that leave consumers open to more out-of-pocket costs, lead to mounting medical debt for consumers.
The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market.